Medline (MDLN) Q4 Net Sales Rise 14.8% to $7.8B Following Completion of IPO

Medline's 14.8% QoQ revenue surge to $7.8B positions it as one of the largest post-IPO medical supply distributors by revenue scale, annualizing near $31B — a figure that rivals Cardinal Health and McKesson growth trajectories in their early public phases. However, the company carries significant LBO-era debt (~$34B leverage from the 2021 Blackstone/Carlyle/Hellman & Friedman buyout), which creates material interest coverage sensitivity in the current rate environment and compresses net margin even against strong top-line momentum. The 14.8% growth rate is exceptional for a distributor at this scale, suggesting market share gains via GPO contracts and hospital system consolidation tailwinds, but sustainability of this growth rate must be validated across 2-3 more quarters. Post-IPO price discovery dynamics, combined with likely 180-day lock-up overhang, introduce a structural selling pressure window that historically suppresses multiple expansion regardless of fundamental strength. ⚡ DEEP SONNET: Wait for post-earnings consolidation; target entry 5-8% below current post-announcement price, ideally near the IPO reference price level which typically acts as magnetic support in early post-IPO windows. Optimal accumulation window is 30-45 days post-announcement after initial momentum fades. | TP:18% SL:9% | 4-6 months, with reassessment at lock-up expiration | Risk:HIGH — Post-IPO lock-up expiration (likely 90-180 days out) represents the single largest near-term risk as early PE sponsors Blackstone, Carlyle, and Hellman & Friedman hold substantial stakes with cost basis well below likely IPO pricing. Additionally, the debt service burden from the LBO is a persistent margin headwind; if rates remain elevated, refinancing risk materializes in 2025-2026 windows. Limited public trading history prevents reliable technical support/resistance mapping. | Sizing:CONSERVATIVE